Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy

References

• FokkensWJ, LundVJ, HopkinsC, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(1):1–464. doi:10.4193/Rhin20.401
   Web of Science ®Google Scholar
• BenjaminMR, StevensWW, LiN, et al. Clinical characteristics of patients with chronic rhinosinusitis without nasal polyps in an academic setting. J Allergy Clin Immunol Pract. 2019;7(3):1010–1016. doi:10.1016/j.jaip.2018.10.01430368005
   PubMed Web of Science ®Google Scholar
• WeiB, LiuF, ZhangJ, et al. Multivariate analysis of inflammatory endotypes in recurrent nasal polyposis in a Chinese population. Rhinology. 2018;56(3):216–226. doi:10.4193/Rhin17.24029785413
   PubMed Web of Science ®Google Scholar
• KariyawasamHH, RotirotiG. Allergic rhinitis, chronic rhinosinusitis and asthma: unravelling a complex relationship. Curr Opin Otolaryngol Head Neck Surg. 2013;21(1):79–86. doi:10.1097/MOO.0b013e32835ac64023241653
   PubMed Web of Science ®Google Scholar
• SamitasK, CarterA, KariyawasamHH, XanthouG. Upper and lower airway remodelling mechanisms in asthma, allergic rhinitis and chronic rhinosinusitis: the one airway concept revisited. Allergy. 2018;73:993–1002.29197105
   PubMed Web of Science ®Google Scholar
• LamEP, KariyawasamHH, RanaBM, et al. IL-25/IL-33-responsive T2 cells characterize nasal polyps with a default T17 signature in nasal mucosa. J Allergy Clin Immunol. 2015.
   Web of Science ®Google Scholar
• TanBK, LiQZ, SuhL, et al. Evidence for intranasal antinuclear autoantibodies in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2011;128(6):1198–1206.e1191. doi:10.1016/j.jaci.2011.08.03721996343
   PubMed Web of Science ®Google Scholar
• WhiteAA, StevensonDD. Aspirin-exacerbated respiratory disease. N Engl J Med. 2018;379(11):1060–1070. doi:10.1056/NEJMra171212530207919
   PubMed Web of Science ®Google Scholar
• Van ZeleT, GevaertP, WateletJB, et al. Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. J Allergy Clin Immunol. 2004;114(4):981–983. doi:10.1016/j.jaci.2004.07.01315480349
   PubMed Web of Science ®Google Scholar
• BaptistAP, NyenhuisS. Rhinitis in the elderly. Immunol Allergy Clin North Am. 2016;36(2):343–357. doi:10.1016/j.iac.2015.12.01027083107
   PubMed Web of Science ®Google Scholar
• TanBK, ZirkleW, ChandraRK, et al. Atopic profile of patients failing medical therapy for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2011;1(2):88–94. doi:10.1002/alr.2002521731824
   PubMed Web of Science ®Google Scholar
• Van LanckerJA, YarnoldPA, DittoAM, et al. Aeroallergen hypersensitivity: comparing patients with nasal polyps to those with allergic rhinitis. Allergy Asthma Proc. 2005;26:109–112.15971468
   PubMed Web of Science ®Google Scholar
• ChangEH, SternDA, WillisAL, et al. Early life risk factors for chronic sinusitis: a longitudinal birth cohort study. J Allergy Clin Immunol. 2018;141(4):1291–1297.e1292. doi:10.1016/j.jaci.2017.11.05229355680
   PubMed Web of Science ®Google Scholar
• SettipaneGA, ChafeeFH. Nasal polyps in asthma and rhinitis. A review of 6037 patients. J Allergy Clin Immunol. 1977;59(1):17–21. doi:10.1016/0091-6749(77)90171-3833373
   PubMed Web of Science ®Google Scholar
• BunnagC, PachareeP, VipulakomP, SiriyanandaC. A study of allergic factor in nasal polyp patients. Ann Allergy. 1983;50:126–132.6824200
   PubMedGoogle Scholar
• JohanssonL, AkerlundA, HolmbergK, et al. Prevalence of nasal polyps in adults: the Skovde population-based study. Ann Otol Rhinol Laryngol. 2003;112(7):625–629. doi:10.1177/00034894031120070912903683
   PubMed Web of Science ®Google Scholar
• BachertC, GevaertP, HoltappelsG, et al. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol. 2001;107(4):607–614. doi:10.1067/mai.2001.11237411295647
   PubMed Web of Science ®Google Scholar
• PearlmanAN, ChandraRK, ChangD, et al. Relationships between severity of chronic rhinosinusitis and nasal polyposis, asthma, and atopy. Am J Rhinol Allergy. 2009;23(2):145–148. doi:10.2500/ajra.2009.23.328419401038
   PubMed Web of Science ®Google Scholar
• GouldHJ, SuttonBJ, BeavilAJ, et al. The biology of IgE and the basis of allergic disease. Annu Rev Immunol. 2003;21(1):579–628. doi:10.1146/annurev.immunol.21.120601.14110312500981
   PubMed Web of Science ®Google Scholar
• SuttonBJ, DaviesAM. Structure and dynamics of IgE-receptor interactions: fcepsilonRI and CD23/FcepsilonRII. Immunol Rev. 2015;268(1):222–235. doi:10.1111/imr.1234026497523
   PubMed Web of Science ®Google Scholar
• JohnsCB, LaidlawTM. Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease. Am J Rhinol Allergy. 2014;28(4):287–289. doi:10.2500/ajra.2014.28.405425197914
   PubMed Web of Science ®Google Scholar
• Eckl-DornaJ, PreeI, ReisingerJ, et al. The majority of allergen-specific IgE in the blood of allergic patients does not originate from blood-derived B cells or plasma cells. Clin Exp Allergy. 2012;42(9):1347–1355. doi:10.1111/j.1365-2222.2012.04030.x22925321
   PubMed Web of Science ®Google Scholar
• GevaertP, Nouri-AriaKT, WuH, et al. Local receptor revision and class switching to IgE in chronic rhinosinusitis with nasal polyps. Allergy. 2013;68(1):55–63. doi:10.1111/all.1205423157682
   PubMed Web of Science ®Google Scholar
• DaviesJM, Platts-MillsTA, AalberseRC. The enigma of IgE+ B-cell memory in human subjects. J Allergy Clin Immunol. 2013;131(4):972–976. doi:10.1016/j.jaci.2012.12.156923398655
   PubMed Web of Science ®Google Scholar
• CrottyS. T follicular helper cell biology: a decade of discovery and diseases. Immunity. 2019;50(5):1132–1148. doi:10.1016/j.immuni.2019.04.01131117010
   PubMed Web of Science ®Google Scholar
• SmurthwaiteL, WalkerSN, WilsonDR, et al. Persistent IgE synthesis in the nasal mucosa of hay fever patients. Eur J Immunol. 2001;31(12):3422–3431. doi:10.1002/1521-4141(200112)31:12<3422::AID-IMMU3422>3.0.CO;2-T11745361
   PubMed Web of Science ®Google Scholar
• TakharP, SmurthwaiteL, CokerHA, et al. Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol. 2005;174(8):5024–5032. doi:10.4049/jimmunol.174.8.502415814733
   PubMed Web of Science ®Google Scholar
• TakharP, CorriganCJ, SmurthwaiteL, et al. Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol. 2007;119(1):213–218. doi:10.1016/j.jaci.2006.09.04517208604
   PubMed Web of Science ®Google Scholar
• ZhangYN, SongJ, WangH, et al. Nasal IL-4(+)CXCR5(+)CD4(+) T follicular helper cell counts correlate with local IgE production in eosinophilic nasal polyps. J Allergy Clin Immunol. 2016;137(2):462–473. doi:10.1016/j.jaci.2015.07.02526329514
   PubMed Web of Science ®Google Scholar
• ChenJB, JamesLK, DaviesAM, et al. Antibodies and superantibodies in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2017;139(4):1195–1204.e1111. doi:10.1016/j.jaci.2016.06.06627658758
   PubMed Web of Science ®Google Scholar
• PrestaLG, LahrSJ, ShieldsRL, et al. Humanization of an antibody directed against IgE. J Immunol. 1993;151:2623–2632.8360482
   PubMed Web of Science ®Google Scholar
• HookWA, ZinsserFU, BerensteinEH, SiraganianRP. Monoclonal antibodies defining epitopes on human IgE. Mol Immunol. 1991;28(6):631–639. doi:10.1016/0161-5890(91)90132-41713647
   PubMed Web of Science ®Google Scholar
• WrightJD, ChuHM, HuangCH, et al. Structural and physical basis for anti-IgE therapy. Sci Rep. 2015;5(1):11581. doi:10.1038/srep1158126113483
   PubMed Web of Science ®Google Scholar
• GevaertP, OmachiTA, CorrenJ, et al. Efficacy and safety of omalizumab in nasal polyposis: two randomized Phase III trials. J Allergy Clin Immunol. 2020;146(3):595–605. doi:10.1016/j.jaci.2020.05.03232524991
   PubMed Web of Science ®Google Scholar
• Vennera MdelC, PicadoC, MullolJ, et al. Efficacy of omalizumab in the treatment of nasal polyps. Thorax. 2011;66(9):824–825. doi:10.1136/thx.2010.15283521109700
   PubMed Web of Science ®Google Scholar
• PintoJM, MehtaN, DiTineoM, et al. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010;48(3):318–324. doi:10.4193/Rhin09.14421038023
   PubMed Web of Science ®Google Scholar
• GevaertP, CalusL, VanZT, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110–116. doi:10.1016/j.jaci.2012.07.04723021878
   PubMed Web of Science ®Google Scholar
• BidderT, SahotaJ, RennieC, et al. Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study. Rhinology. 2018;56(1):42–45. doi:10.4193/Rhin17.13929288573
   PubMed Web of Science ®Google Scholar
• LePT, SolerZM, JonesR, et al. Systematic review and meta-analysis of SNOT-22 outcomes after surgery for chronic rhinosinusitis with nasal polyposis. Otolaryngol Head Neck Surg. 2018;159(3):414–423. doi:10.1177/019459981877306529712509
   PubMed Web of Science ®Google Scholar
• AgacheI, RochaC, BeltranJ, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: a systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1043–1057. doi:10.1111/all.1423532064642
   PubMed Web of Science ®Google Scholar
• Serrano-CandelasE, Martinez-ArangurenR, ValeroA, et al. Comparable actions of omalizumab on mast cells and basophils. Clin Exp Allergy. 2016;46(1):92–102. doi:10.1111/cea.1266826509363
   PubMed Web of Science ®Google Scholar
• PrussinC, GriffithDT, BoeselKM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003;112(6):1147–1154. doi:10.1016/j.jaci.2003.10.00314657874
   PubMed Web of Science ®Google Scholar
• LinH, BoeselKM, GriffithDT, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol. 2004;113(2):297–302. doi:10.1016/j.jaci.2003.11.04414767445
   PubMed Web of Science ®Google Scholar
• DjukanovicR, WilsonSJ, KraftM, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170(6):583–593. doi:10.1164/rccm.200312-1651OC15172898
   PubMed Web of Science ®Google Scholar
• SahotaJ, BidderT, LivingstonR, et al. Chronic rhinosinusitis and omalizumab: eosinophils not IgE predict treatment response in real-life. Rhinology. 2018;1(1):147–153. doi:10.4193/RHINOL/18.077
   Google Scholar
• ForoughiS, FosterB, KimN, et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol. 2007;120(3):594–601. doi:10.1016/j.jaci.2007.06.01517765756
   PubMed Web of Science ®Google Scholar
• GarciaG, MagnanA, ChironR, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest. 2013;144(2):411–419. doi:10.1378/chest.12-196123579324
   PubMed Web of Science ®Google Scholar
• TakakuY, SomaT, NishiharaF, et al. Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma. Int Arch Allergy Immunol. 2013;161(Suppl s2):107–117. doi:10.1159/00035085223711861
   PubMed Web of Science ®Google Scholar
• SkiepkoR, ZietkowskiZ, LukaszykM, et al. Changes in blood eosinophilia during omalizumab therapy as a predictor of asthma exacerbation. Postepy Dermatol Alergol. 2014;31:305–309. doi:10.5114/pdia.2014.4097325395927
   PubMed Web of Science ®Google Scholar
• NogaO, HanfG, BrachmannI, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol. 2006;117(6):1493–1499. doi:10.1016/j.jaci.2006.02.02816751018
   PubMed Web of Science ®Google Scholar
• van RensenEL, EvertseCE, van SchadewijkWA, et al. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy. 2009;64(1):72–80. doi:10.1111/j.1398-9995.2008.01881.x19076931
   PubMed Web of Science ®Google Scholar
• GolebskiK, van TongerenJ, van EgmondD, et al. Specific induction of TSLP by the viral RNA analogue poly(I:C) in primary epithelial cells derived from nasal polyps. PLoS One. 2016;11(4):e0152808. doi:10.1371/journal.pone.015280827050744
   PubMed Web of Science ®Google Scholar
• GillMA, LiuAH, CalatroniA, et al. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol. 2018;141(5):1735–1743.e1739. doi:10.1016/j.jaci.2017.07.03528870461
   PubMed Web of Science ®Google Scholar
• AslanF, AltunE, PaksoyS, TuranG. Could Eosinophilia predict clinical severity in nasal polyps? Multidiscip Respir Med. 2017;12(1):21. doi:10.1186/s40248-017-0102-728835819
   PubMed Web of Science ®Google Scholar
• HaughneyJ, MoriceA, BlythKG, et al. A retrospective cohort study in severe asthma describing commonly measured biomarkers: eosinophil count and IgE levels. Respir Med. 2018;134:117–123. doi:10.1016/j.rmed.2017.12.00129413497
   PubMed Web of Science ®Google Scholar
• TomassenP, VandeplasG, Van ZeleT, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449–1456.e1444. doi:10.1016/j.jaci.2015.12.132426949058
   PubMed Web of Science ®Google Scholar
• KariyawasamHH. Chronic rhinosinusitis with nasal polyps: insights into mechanisms of disease from emerging biological therapies. Expert Rev Clin Immunol. 2019;15(1):59–71. doi:10.1080/1744666X.2019.154173830370785
   PubMed Web of Science ®Google Scholar
• KariyawasamHH, JamesLK, GaneSB. Dupilumab: clinical efficacy of blocking IL-4/IL-13 signalling in chronic rhinosinusitis with nasal polyps. Drug Des Devel Ther. 2020;14:1757–1769. doi:10.2147/DDDT.S243053
   PubMed Web of Science ®Google Scholar
• CasaleTB, ChippsBE, RosenK, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490–497. doi:10.1111/all.1330228859263
   PubMed Web of Science ®Google Scholar
• HumbertM, TailleC, MalaL, et al. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018;51.
   Web of Science ®Google Scholar
• TurkM, KocaturkE, CureK, YilmazI. Two-week intervals during omalizumab treatment may provide better symptom control in selected patients with chronic urticaria. J Allergy Clin Immunol Pract. 2018;6(4):1389–1390. doi:10.1016/j.jaip.2018.01.02729410306
   PubMed Web of Science ®Google Scholar
• HochhausG, BrookmanL, FoxH, et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin. 2003;19(6):491–498. doi:10.1185/03007990312500217114594521
   PubMed Web of Science ®Google Scholar
• CasaleTB. Anti-immunoglobulin E (omalizumab) therapy in seasonal allergic rhinitis. Am J Respir Crit Care Med. 2001;164(supplement_1):S18–21. doi:10.1164/ajrccm.164.supplement_1.210302311704613
   PubMed Web of Science ®Google Scholar
• LowePJ, TannenbaumS, GautierA, JimenezP. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol. 2009;68(1):61–76. doi:10.1111/j.1365-2125.2009.03401.x19660004
   PubMed Web of Science ®Google Scholar
• GehaRS, HelmB, GouldH. Inhibition of the Prausnitz-Kustner reaction by an immunoglobulin epsilon-chain fragment synthesized in E coli. Nature. 1985;315(6020):577–578. doi:10.1038/315577a03925344
   PubMed Web of Science ®Google Scholar
• DaviesAM, AllanEG, KeebleAH, et al. Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab. J Biol Chem. 2017;292(24):9975–9987. doi:10.1074/jbc.M117.77647628438838
   PubMed Web of Science ®Google Scholar